English translation of the German original minutes Minutes of the 22nd Annual General Meeting of Basilea Pharmaceutica Ltd , held on April. | May 4, 2023
Press Release Basel, Switzerland, April 13, 2022 Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that shareholders approved all proposals of the board of directors at today's annual general
Investegate announcements from Basilea Pharmaceutica AG, Basilea shareholders approve all proposals of the board of directors at the annual general meeting
65% year-on-year growth in non-deferred revenue from Cresemba and Zevtera Operating profit of CHF 1.2 million Future strategic focus on anti-infectives.
65% year-on-year growth in non-deferred revenue from Cresemba and Zevtera Operating profit of CHF 1.2 million Future strategic focus on anti-infectives Exploring strategic options to maximize the value